← 產業報告目錄

Neurovascular Devices Market by Disease Pathology (Cerebral Aneurysm (Embolic coils, Flow Diverters), Ischemic Stroke (Clot Retriever, Aspiration, Snare), Carotid Stenosis (Stent, Embolic Protection), Others), End User (Hospitals) - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2025-11-06頁數 307報告編號 MD1310

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global neurovascular devices market is projected to reach USD 7.22 billion in 2030 from USD 4.64 billion in 2025, at a CAGR of 9.3 % during the forecast period. The rising prevalence of neurovascular diseases, driven by factors like aging populations, hypertension, smoking, and sedentary lifestyles, is significantly increasing the demand for advanced tools for effective monitoring and treatment. As the incidence of conditions such as stroke, brain aneurysms, and arteriovenous malformations grows, so does the need for timely diagnosis and minimally invasive procedures. The expanding elderly population, which faces higher risks for these conditions, further drives the demand for neurovascular devices. Technological innovations are enhancing these devices to be more efficient, accurate, and appealing to both healthcare professionals and patients. However, wider adoption of these solutions may be limited by high treatment costs, a shortage of skilled neurosurgeons, and a strict regulatory approval process for medical devices. Based on disease pathology, the cerebral aneurysm segment is expected to account for the largest share of the global neurovascular devices market. Based on disease pathology, the global neurovascular devices market is divided into five main segments: cerebral aneurysms, ischemic strokes, carotid artery stenosis, arteriovenous malformation & fistulas, and other disease pathologies. The cerebral aneurysms segment held the largest share of the market. The high occurrence of cerebral aneurysms results from lifestyle, physiological, and genetic factors. Chronic hypertension, smoking, and atherosclerosis greatly weaken blood vessel walls, while habits like alcohol intake and a sedentary lifestyle increase vascular stress. Age and gender also play a role, with middle-aged individuals and women facing higher risks. Furthermore, those with a family history of aneurysms or certain genetic disorders are more likely to develop these conditions, making genetics a key underlying factor. Based on end user, the hospitals & ambulatory surgical centres segment is expected to account for the largest share of the global neurovascular devices market. Based on end user, the global neurovascular devices market is segmented by end user into the following categories: hospitals & ambulatory surgical centres, specialty clinics, research and academic institutes. Among these, the hospital and ambulatory surgical center segment is expected to capture the largest market share. They have the latest diagnostic tools and experienced, well-trained medical teams to handle critical conditions like strokes, aneurysms, and vascular malformations. Hospitals and surgical centers provide fast, specialized care, which is often essential in time-sensitive situations. Their ability to offer continuous monitoring, rehabilitation services, and manage complications ensures optimal patient outcomes, which is the main reason for their leading position in the market landscape. The Asia Pacific is expected to grow at the highest CAGR in the neurovascular devices market during the forecast period. The rapid rise in neurovascular disease cases and the increasing demand for advanced treatments are driving high demand for neurovascular devices in the Asia Pacific region. Additionally, global leaders in neurovascular devices are expanding their presence in APAC by introducing advanced formulations to develop robotic systems that enhance patient outcomes in complex hemorrhagic cases and urgent ischemic issues, as well as strokes. A breakdown of the primary participants (supply side) for the neurovascular devices market referred to in this report is provided below: • By Company Type: Tier 1 (30%), Tier 2 (35%), and Tier 3 (35%) • By Designation: C-level Executives (20%), Directors (35%), and Others (45%) • By Region: North America (30%), Europe (25%), Asia Pacific (20%), Latin America (20%), Middle East & Africa (2%), GCC Countries (3%) Prominent players in the diabetes care devices market include Stryker (US), Medtronic (Ireland), Johnson & Johnson (US), Terumo Corporation (Japan), Penumbra (US), MicroPort Scientific Corporation (China), Balt Group (France), Kaneka Corporation (Japan), Phenox GmbH (Wallaby Medical), Asahi Intecc Co., Ltd (Japan), Achieva Medical (Peijia Medical) (China), Rapid Medical (Israel), Japan Lifeline (Japan), Acandis GmbH (Germany), Evasc Medical System Corp (Canada), Sensome (France), Lepu Medical Technology (Beijing) Co., Ltd (China), Imperative Care, Inc. (US), Medikit Co., Ltd (Japan), Zylox-Tonbridge Medical Co., Ltd (China), Neurosafe Medical Co., Ltd (China), Luseed Vascular (Israel), NeuroVasc Technologies, Inc. (US), Oxford Endovascular (UK), and Galaxy Therapeutics (US). Research Coverage The report provides an analysis of the neurovascular devices market, focusing on the estimation of market size and future growth potential across different segments, including disease pathology, end users, and regions. It also includes a competitive analysis of major market players, highlighting their company profiles, product and service offerings, recent developments, and key market insights strategies. Reasons to Buy the Report The report provides valuable insights for both market leaders and new entrants in the diabetes care devices industry, including estimated revenue figures for the overall market and its subsegments. It helps stakeholders understand the competitive landscape, enabling them to better position their businesses and develop effective go-to-market strategies. Additionally, the report highlights key market drivers, restraints, challenges, and opportunities, helping stakeholders assess the current state of the market. This report provides insights into the following pointers:  Analysis of key drivers (Rising incidence of neurovascular diseases, Availability of medical reimbursements for neurovascular procedures, Expansion of healthcare infrastructure across emerging economies, Rising demand for effective neurovascular therapies) restraints (Dearth of skilled neurosurgeons, High procedural cost of neurovascular surgeries and associated products), opportunities (Advancement of AI- and robot-assisted systems for next-generation neurointerventions, Growing preference for minimally neurosurgical procedures) and challenges (Stringent regulatory approval process for medical devices). • Market Penetration: It provides detailed information on the product portfolios offered by major players in the global neurovascular devices market. The report covers various segments, including disease pathology, end user, and regions. • Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global neurovascular devices market. • Market Development: Thorough knowledge and analysis of the profitable rising markets by disease pathology, end user, and regions. • Market Diversification: Comprehensive information about newly launched products and services, expanding markets, current advancements, and investments in the global neurovascular devices market. • Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products and services, and capacities of the major competitors in the global neurovascular devices market.
目錄 Table of Contents
1 INTRODUCTION 30 1.1 STUDY OBJECTIVES 30 1.2 MARKET DEFINITION 30 1.3 MARKET SCOPE 31 1.3.1 INCLUSIONS AND EXCLUSIONS 31 1.3.2 MARKETS COVERED & REGIONAL SCOPE 32 1.3.3 YEARS CONSIDERED 33 1.4 CURRENCY 33 1.5 LIMITATIONS 34 1.6 SUMMARY OF CHANGES 34 2 EXECUTIVE SUMMARY 35 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 35 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & DEVELOPMENTS 36 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 37 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 38 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 39 3 PREMIUM INSIGHTS 40 3.1 NEUROVASCULAR DEVICES MARKET OVERVIEW 40 3.2 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY TYPE AND COUNTRY 41 3.3 NEUROVASCULAR DEVICES MARKET: GEOGRAPHICAL MIX 42 3.4 NEUROVASCULAR DEVICES MARKET: REGIONAL MIX 42 3.5 NEUROVASCULAR DEVICES MARKET: DEVELOPED VS. EMERGING MARKETS 43 4 MARKET OVERVIEW 44 4.1 INTRODUCTION 44 4.2 MARKET DYNAMICS 44 4.2.1 DRIVERS 45 4.2.1.1 Increase in incidence of neurovascular diseases 45 4.2.1.2 Availability of medical reimbursements for neurovascular procedures 45 4.2.1.3 Expansion of healthcare infrastructure across emerging economies 46 4.2.1.4 Rise in demand for effective neurovascular technologies 46 4.2.2 RESTRAINTS 47 4.2.2.1 Dearth of skilled neurosurgeons 47 4.2.2.2 High procedural cost of neurovascular surgeries and associated products 47   4.2.3 OPPORTUNITIES 48 4.2.3.1 Advancement of AI- and robot-assisted systems for next-generation neurointerventions 48 4.2.4 CHALLENGES 48 4.2.4.1 Stringent regulatory approval process for medical devices 48 4.3 UNMET NEEDS AND WHITE SPACES 49 4.3.1 UNMET NEEDS 49 4.3.2 WHITE SPACE OPPORTUNITIES 49 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 49 4.4.1 INTERCONNECTED MARKETS 49 4.4.2 CROSS-SECTOR OPPORTUNITIES 50 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 50 5 INDUSTRY TRENDS 51 5.1 PORTER’S FIVE FORCES ANALYSIS 51 5.1.1 INTENSITY OF COMPETITIVE RIVALRY 52 5.1.2 BARGAINING POWER OF SUPPLIERS 52 5.1.3 BARGAINING POWER OF BUYERS 52 5.1.4 THREAT OF SUBSTITUTES 53 5.1.5 THREAT OF NEW ENTRANTS 53 5.2 MACROECONOMIC OUTLOOK 53 5.2.1 INTRODUCTION 53 5.2.2 GDP TRENDS AND FORECAST 53 5.2.3 TRENDS IN NEUROVASCULAR DEVICES MARKET 55 5.3 SUPPLY CHAIN ANALYSIS 55 5.4 VALUE CHAIN ANALYSIS 57 5.5 ECOSYSTEM ANALYSIS 58 5.6 PRICING ANALYSIS 60 5.6.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY DISEASE PATHOLOGY 60 5.6.2 AVERAGE SELLING PRICE TREND OF NEUROVASCULAR DEVICES, BY REGION 62 5.7 TRADE ANALYSIS 63 5.7.1 IMPORT DATA FOR HS CODE 901890, 2020–2024 63 5.7.2 EXPORT DATA FOR HS CODE 901890, 2020–2024 63 5.8 KEY CONFERENCES & EVENTS, 2025–2026 64 5.9 TRENDS/DISRUPTIONS IMPACTING CONSUMERS’ BUSINESSES 64 5.10 INVESTMENT & FUNDING SCENARIO 65 5.11 CASE STUDY ANALYSIS 66 5.11.1 FLOW DIVERTER FOR COMPLEX INTRACRANIAL ANEURYSMS 66 5.11.2 ADVANCED FLOW DIVERTER WITH ENHANCED DELIVERABILITY 66 5.11.3 STENT RETRIEVER THROMBECTOMY FOR ACUTE IN-STENT THROMBOSIS 66   5.12 IMPACT OF 2025 US TARIFFS ON NEUROVASCULAR DEVICES MARKET 67 5.12.1 INTRODUCTION 67 5.12.2 KEY TARIFF RATES 68 5.12.3 PRICE IMPACT ANALYSIS 68 5.12.4 IMPACT ON COUNTRIES AND REGIONS 69 5.12.4.1 US 69 5.12.4.2 Europe 69 5.12.4.3 Asia Pacific 70 5.12.5 IMPACT ON END-USER INDUSTRIES 70 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, AND INNOVATIONS 71 6.1 KEY EMERGING TECHNOLOGIES 71 6.1.1 NEGATIVE PRESSURE CLOT REMOVAL TECHNOLOGY 71 6.2 COMPLEMENTARY TECHNOLOGIES 71 6.2.1 DIGITAL HEALTH AND REMOTE MONITORING PLATFORMS 71 6.3 TECHNOLOGY/PRODUCT ROADMAP 72 6.3.1 SHORT-TERM (2025–2027) | FOUNDATION & EARLY COMMERCIALIZATION 72 6.3.2 MID-TERM (2027–2030) | EXPANSION & STANDARDIZATION 72 6.3.3 LONG-TERM (2030–2035+) | MASS COMMERCIALIZATION & DISRUPTION 73 6.4 PATENT ANALYSIS 73 6.4.1 PATENT PUBLICATION TRENDS FOR NEUROVASCULAR DEVICES MARKET 73 6.4.2 JURISDICTION ANALYSIS: TOP APPLICANTS FOR PATENTS IN NEUROVASCULAR DEVICES MARKET 74 6.4.3 LIST OF MAJOR PATENTS 75 6.5 IMPACT OF AI/GEN AI ON NEUROVASCULAR DEVICES MARKET 76 6.5.1 TOP USE CASES AND MARKET POTENTIAL 76 6.5.2 TOP CASE STUDIES OF AI IMPLEMENTATION IN NEUROVASCULAR DEVICES MARKET 77 6.5.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 77 6.5.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN NEUROVASCULAR DEVICES MARKET 77 6.6 SUCCESS STORIES AND REAL-WORLD APPLICATIONS 78 6.6.1 RAPID MEDICAL – AI-POWERED ROBOTIC THROMBECTOMY 78 6.6.2 AIDOC – AI IMAGING & STROKE WORKFLOW ACCELERATION 78 6.6.3 RAPIDAI – AI-DRIVEN NEUROVASCULAR IMAGING 78   7 REGULATORY LANDSCAPE 79 7.1 REGIONAL REGULATIONS AND COMPLIANCE 79 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79 7.1.2 INDUSTRY STANDARDS 81 7.1.2.1 North America 81 7.1.2.1.1 US 81 7.1.2.1.2 Canada 81 7.1.2.2 Europe 82 7.1.2.3 Asia Pacific 82 7.1.2.3.1 China 82 7.1.2.3.2 Japan 82 7.1.2.3.3 India 82 7.1.2.4 Latin America 82 7.1.2.4.1 Brazil 83 7.1.2.4.2 Mexico 83 7.1.2.5 Middle East 83 7.1.2.6 Africa 83 7.2 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 84 7.2.1 CERTIFICATIONS, LABELING, AND ECO-STANDARDS IN NEUROVASCULAR DEVICES MARKET 84 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 85 8.1 DECISION-MAKING PROCESS 85 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 85 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 85 8.2.2 KEY BUYING CRITERIA 86 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 87 8.4 UNMET NEEDS IN END USERS 88 8.5 MARKET PROFITABILITY 89 8.5.1 REVENUE POTENTIAL 89 8.5.2 COST DYNAMICS 89 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 90 9 NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY 91 9.1 INTRODUCTION 92 9.2 CEREBRAL ANEURYSMS 92 9.2.1 EMBOLIC COILS 93 9.2.2 BARE DETACHABLE COILS 95 9.2.2.1 Significant adoption of bare detachable coils by neurosurgeons for brain aneurysm treatment to promote growth 95 9.2.3 COATED DETACHABLE COILS 96 9.2.3.1 High cost of coated detachable coils to limit adoption 96 9.2.4 FLOW DIVERSION DEVICES 97 9.2.4.1 Rising R&D activities to develop novel flow diversion devices to promote growth 97 9.2.5 INTRACRANIAL STENTS 98 9.2.5.1 Increased efficacy of stent-assisted coiling for treatment of wide-necked intracranial aneurysms to boost adoption 98 9.2.6 OTHER DEVICES 99 9.3 ISCHEMIC STROKES 100 9.3.1 CLOT RETRIEVER DEVICES 101 9.3.1.1 Proven clinical effectiveness in treating large clots and increase in number of clinical trials aimed at validating their use in ischemic stroke treatment to drive market 101 9.3.2 SUCTION & ASPIRATION DEVICES 102 9.3.2.1 Rapid commercialization of technologically advanced aspiration devices for ischemic stroke treatment to support market 102 9.3.3 VASCULAR SNARES 103 9.3.3.1 Limited procedural benefits in stroke treatment to limit adoption of vascular snares 103 9.3.4 BALLOON CATHETERS 104 9.3.4.1 Growing recognition of benefits associated with balloon catheters to bolster demand 104 9.3.5 OTHER DEVICES 104 9.4 CAROTID ARTERY STENOSIS 105 9.4.1 CAROTID ARTERY STENTS 106 9.4.1.1 Growing adoption of carotid artery stents for carotid intervention procedures to support growth 106 9.4.2 EMBOLIC PROTECTION DEVICES 108 9.4.2.1 Growing utilization of distal filters during carotid intervention procedures to promote growth 108 9.4.3 BALLOON CATHETERS 108 9.4.3.1 Growing preference for balloon catheters to improve efficacy of carotid intervention procedures to augment growth 108 9.5 ARTERIOVENOUS MALFORMATION & FISTULAS 109 9.5.1 LIQUID EMBOLIC AGENTS 110 9.5.1.1 Development of novel liquid embolic agents offering high embolization of arteriovenous fistulas to support growth 110 9.5.2 OCCLUSION BALLOON CATHETERS 111 9.5.2.1 Growing utilization of balloon catheters for AVM treatment to support growth 111 9.5.3 MICROCATHETERS 111 9.5.3.1 Improved compatibility of microcatheters with embolic agents to boost demand 111 9.6 OTHER DISEASE PATHOLOGIES 112   10 NEUROVASCULAR DEVICES MARKET, BY END USER 113 10.1 INTRODUCTION 114 10.2 HOSPITALS AND AMBULATORY SURGICAL CENTERS 114 10.2.1 INCREASING VOLUME OF NEUROVASCULAR PROCEDURES DUE TO AVAILABILITY OF ADVANCED EQUIPMENT TO DRIVE MARKET 114 10.3 SPECIALTY CLINICS 115 10.3.1 INCREASE IN NEUROVASCULAR DISEASES TO DRIVE MARKET 115 10.4 RESEARCH AND ACADEMIC INSTITUTES 116 10.4.1 INCREASING COLLABORATIONS FOR DEVELOPMENT OF TECHNOLOGICALLY ADVANCED NEUROVASCULAR DEVICES TO SUPPORT MARKET GROWTH 116 11 NEUROVASCULAR DEVICES MARKET, BY REGION 117 11.1 INTRODUCTION 118 11.2 NORTH AMERICA 119 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 119 11.2.2 US 123 11.2.2.1 Presence of established neurovascular device manufacturers to drive market 123 11.2.3 CANADA 126 11.2.3.1 Large target pool for ischemic stroke patients to drive market 126 11.3 EUROPE 130 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 130 11.3.2 GERMANY 133 11.3.2.1 Rising geriatric population to drive market 133 11.3.3 FRANCE 136 11.3.3.1 Growing preference for minimally invasive neurovascular procedures to drive market 136 11.3.4 UK 139 11.3.4.1 Rising prevalence of stroke to drive market 139 11.3.5 ITALY 142 11.3.5.1 Increasing geriatric population to drive demand for neurovascular devices 142 11.3.6 SPAIN 145 11.3.6.1 Rising stroke burden and strong healthcare investment to drive demand for neurovascular devices market 145 11.3.7 REST OF EUROPE 148 11.4 ASIA PACIFIC 151 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 152 11.4.2 JAPAN 156 11.4.2.1 Increase in healthcare spending to drive market 156 11.4.3 CHINA 159 11.4.3.1 Robust presence of neurovascular device manufacturers to drive market 159   11.4.4 INDIA 162 11.4.4.1 Increase in prevalence of neurovascular diseases to drive uptake for neurovascular devices 162 11.4.5 AUSTRALIA 165 11.4.5.1 Rise in incidence of cerebrovascular disease to drive market 165 11.4.6 SOUTH KOREA 168 11.4.6.1 Health insurance coverage for neurovascular procedures to support market growth 168 11.4.7 REST OF ASIA PACIFIC 170 11.5 LATIN AMERICA 173 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 173 11.5.2 BRAZIL 176 11.5.2.1 Increasing awareness initiatives on stroke symptoms to drive market 176 11.5.3 MEXICO 179 11.5.3.1 Increasing neurovascular diseases to support market growth 179 11.5.4 REST OF LATIN AMERICA 182 11.6 MIDDLE EAST & AFRICA 185 11.6.1 MACROECONOMIC OUTLOOK FOR THE MIDDLE EAST & AFRICA 185 11.6.2 SHORTAGE OF NEUROSURGEONS AND POOR HEALTHCARE COVERAGE TO RESTRAIN MARKET GROWTH 185 11.6.3 GCC COUNTRIES 189 11.6.3.1 Rising stroke prevalence to drive neurovascular devices market in GCC countries 189 11.6.4 REST OF MIDDLE EAST & AFRICA 192 12 COMPETITIVE LANDSCAPE 196 12.1 INTRODUCTION 196 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 196 12.2.1 OVERVIEW OF MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN NEUROVASCULAR DEVICES MARKET 197 12.3 REVENUE ANALYSIS 198 12.4 MARKET SHARE ANALYSIS, 2024 199 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 202 12.5.1 STARS 202 12.5.2 EMERGING LEADERS 202 12.5.3 PERVASIVE PLAYERS 202 12.5.4 PARTICIPANTS 202 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 204 12.5.5.1 Company footprint 204 12.5.5.2 Regional footprint 205 12.5.5.3 Disease pathology footprint 206 12.5.5.4 By end user footprint 207   12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 208 12.6.1 PROGRESSIVE COMPANIES 208 12.6.2 RESPONSIVE COMPANIES 208 12.6.3 DYNAMIC COMPANIES 208 12.6.4 STARTING BLOCKS 208 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 210 12.6.5.1 Detailed list of key startups/SMEs 210 12.6.5.2 Competitive benchmarking of key startups/SMEs 211 12.7 COMPANY VALUATION & FINANCIAL METRICS 211 12.7.1 FINANCIAL METRICS 211 12.7.2 COMPANY VALUATION 212 12.8 BRAND/PRODUCT COMPARISON 213 12.9 R&D EXPENDITURE OF KEY PLAYERS 214 12.10 COMPETITIVE SCENARIO 214 12.10.1 PRODUCT LAUNCHES AND APPROVALS 214 12.10.2 DEALS 216 12.10.3 EXPANSIONS 217 12.10.4 OTHER DEVELOPMENTS 217 13 COMPANY PROFILES 218 13.1 KEY PLAYERS 218 13.1.1 STRYKER 218 13.1.1.1 Business overview 218 13.1.1.2 Products offered 219 13.1.1.3 Recent developments 224 13.1.1.3.1 Product launches & approvals 224 13.1.1.3.2 Deals 225 13.1.1.3.3 Expansions 226 13.1.1.4 MnM view 226 13.1.1.4.1 Key strengths 226 13.1.1.4.2 Strategic choices 226 13.1.1.4.3 Weaknesses and competitive threats 227 13.1.2 MEDTRONIC 228 13.1.2.1 Business overview 228 13.1.2.2 Products offered 229 13.1.2.3 Recent developments 231 13.1.2.3.1 Product launches & approvals 231 13.1.2.3.2 Expansions 232 13.1.2.4 MnM view 232 13.1.2.4.1 Key strengths 232 13.1.2.4.2 Strategic choices 232 13.1.2.4.3 Weaknesses and competitive threats 232 13.1.3 JOHNSON & JOHNSON 233 13.1.3.1 Business overview 233 13.1.3.2 Products offered 234 13.1.3.3 Recent developments 235 13.1.3.3.1 Product launches & approvals 235 13.1.3.3.2 Other developments 236 13.1.3.4 MnM view 237 13.1.3.4.1 Key strengths 237 13.1.3.4.2 Strategic choices 237 13.1.3.4.3 Weaknesses and competitive threats 237 13.1.4 TERUMO CORPORATION 238 13.1.4.1 Business overview 238 13.1.4.2 Products offered 239 13.1.4.3 Recent developments 240 13.1.4.3.1 Product launches & approvals 240 13.1.4.3.2 Deals 242 13.1.4.3.3 Expansions 242 13.1.4.3.4 Other developments 243 13.1.4.4 MnM view 243 13.1.4.4.1 Key strengths 243 13.1.4.4.2 Strategic choices 243 13.1.4.4.3 Weaknesses and competitive threats 243 13.1.5 PENUMBRA, INC. 244 13.1.5.1 Business overview 244 13.1.5.2 Products offered 245 13.1.5.3 Recent developments 246 13.1.5.3.1 Product launches & approvals 246 13.1.5.4 MnM view 247 13.1.5.4.1 Key strengths 247 13.1.5.4.2 Strategic choices 247 13.1.5.4.3 Weaknesses and competitive threats 247 13.1.6 MICROPORT SCIENTIFIC CORPORATION 248 13.1.6.1 Business overview 248 13.1.6.2 Products offered 249 13.1.6.3 Recent developments 250 13.1.6.3.1 Product launches & approvals 250 13.1.6.4 MnM view 250 13.1.6.4.1 Key strengths 250 13.1.6.4.2 Strategic choices 250 13.1.6.4.3 Weaknesses and competitive threats 251   13.1.7 BALT GROUP 252 13.1.7.1 Business overview 252 13.1.7.2 Products offered 252 13.1.7.3 Recent developments 253 13.1.7.3.1 Deals 253 13.1.7.3.2 Expansions 253 13.1.7.4 MnM view 253 13.1.7.4.1 Key strengths 253 13.1.7.4.2 Strategic choices 254 13.1.7.4.3 Weaknesses and competitive threats 254 13.1.8 KANEKA CORPORATION 255 13.1.8.1 Business overview 255 13.1.8.2 Products offered 256 13.1.8.3 Recent developments 257 13.1.8.3.1 Product launches & approvals 257 13.1.8.3.2 Deals 257 13.1.8.4 MnM view 258 13.1.8.4.1 Key strengths 258 13.1.8.4.2 Strategic choices 258 13.1.8.4.3 Weaknesses and competitive threats 258 13.1.9 PHENOX GMBH (WALLABY MEDICAL) 259 13.1.9.1 Business overview 259 13.1.9.2 Products offered 259 13.1.9.3 Recent developments 260 13.1.9.3.1 Product launches & approvals 260 13.1.9.4 MnM view 260 13.1.9.4.1 Key strengths 260 13.1.9.4.2 Strategic choices 261 13.1.9.4.3 Weaknesses and competitive threats 261 13.1.10 ASAHI INTECC CO., LTD 262 13.1.10.1 Business overview 262 13.1.10.2 Products offered 263 13.1.10.3 Recent developments 264 13.1.10.3.1 Deals 264 13.1.10.3.2 Expansions 264 13.1.10.4 MnM view 265 13.1.10.4.1 Key strengths 265 13.1.10.4.2 Strategic choices 265 13.1.10.4.3 Weaknesses and competitive threats 265   13.1.11 ACHIEVA MEDICAL (PEIJIA MEDICAL) 266 13.1.11.1 Business overview 266 13.1.11.2 Products offered 266 13.1.11.3 Recent developments 267 13.1.11.3.1 Deals 267 13.1.12 RAPID MEDICAL 268 13.1.12.1 Business overview 268 13.1.12.2 Products offered 268 13.1.12.3 Recent developments 269 13.1.12.3.1 Product launches & approvals 269 13.1.12.3.2 Deals 269 13.1.13 JAPAN LIFELINE CO., LTD 270 13.1.13.1 Business overview 270 13.1.13.2 Products offered 271 13.1.14 ACANDIS GMBH 272 13.1.14.1 Business overview 272 13.1.14.2 Products offered 272 13.1.14.3 Recent developments 273 13.1.14.3.1 Expansions 273 13.1.15 EVASC MEDICAL SYSTEM CORP 274 13.1.15.1 Business overview 274 13.1.15.2 Products offered 274 13.1.15.3 Recent developments 274 13.1.15.3.1 Product launches & approvals 274 13.1.15.3.2 Expansions 275 13.2 OTHER KEY PLAYERS 276 13.2.1 SENSOME 276 13.2.2 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD. 277 13.2.3 IMPERATIVE CARE, INC. 278 13.2.4 MEDIKIT CO., LTD. 279 13.2.5 ZYLOX-TONBRIDGE MEDICAL CO., LTD. 280 13.3 SMES/STARTUPS 281 13.3.1 NEUROSAFE MEDICAL CO., LTD 281 13.3.2 LUSEED VASCULAR 283 13.3.3 NEUROVASC TECHNOLOGIES, INC. 284 13.3.4 OXFORDENDOVASCULAR 284 13.3.5 GALAXY THERAPEUTICS 285   14 RESEARCH METHODOLOGY 286 14.1 RESEARCH DATA 286 14.1.1 SECONDARY DATA 287 14.1.1.1 Key sources of secondary data 287 14.1.1.2 Key data from secondary sources 288 14.1.2 PRIMARY DATA 288 14.1.2.1 Key primary sources 288 14.1.2.2 Objectives of primary research 289 14.1.2.3 Key data from primary sources 289 14.1.2.4 Key industry insights 290 14.1.2.5 Breakdown of primaries 290 14.2 MARKET SIZE ESTIMATION 291 14.3 DATA TRIANGULATION 297 14.4 MARKET SHARE ESTIMATION 297 14.5 RESEARCH ASSUMPTIONS 298 14.6 FACTOR ANALYSIS 298 14.7 RESEARCH LIMITATIONS 299 14.7.1 SCOPE-RELATED LIMITATIONS 299 14.7.2 METHODOLOGY-RELATED LIMITATIONS 299 14.8 RISK ASSESSMENT 299 14.9 METHODOLOGY-RELATED LIMITATIONS 299 15 APPENDIX 300 15.1 DISCUSSION GUIDE 300 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 303 15.3 CUSTOMIZATION OPTIONS 305 15.4 RELATED REPORTS 305 15.5 AUTHOR DETAILS 306
圖表清單 List of Tables & Figures
TABLE 1 STANDARD CURRENCY CONVERSION RATES 33 TABLE 2 NEUROVASCULAR DEVICES MARKET: UNMET NEEDS 49 TABLE 3 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 50 TABLE 4 NEUROVASCULAR DEVICES MARKET: PORTER’S FIVE FORCES 52 TABLE 5 GDP PERCENTAGE CHANGE, BY KEY COUNTRY, 2021–2030 54 TABLE 6 ROLE IN ECOSYSTEM: NEUROVASCULAR DEVICES MARKET 59 TABLE 7 AVERAGE SELLING PRICE TREND OF STENT RETRIEVERS, BY COMPANY, 2023–2025 (USD) 60 TABLE 8 AVERAGE SELLING PRICE TREND OF CAROTID ARTERY STENTS, BY COMPANY, 2023–2025 (USD) 60 TABLE 9 AVERAGE SELLING PRICE TREND OF ASPIRATION DEVICES, BY COMPANY, 2023–2025 (USD) 61 TABLE 10 AVERAGE SELLING PRICE TREND OF MICROCATHETERS, BY COMPANY, 2023–2025 (USD) 61 TABLE 11 AVERAGE SELLING PRICE TREND OF BALLOON CATHETERS, BY COMPANY, 2023–2025 (USD) 61 TABLE 12 AVERAGE SELLING PRICE TREND OF NEUROVASCULAR DEVICES, BY REGION, 2022–2024 (USD) 62 TABLE 13 IMPORT DATA FOR HS CODE 901890, BY COUNTRY, 2020–2024 (USD THOUSAND) 63 TABLE 14 EXPORT DATA FOR HS CODE 901890, BY COUNTRY, 2020–2024 (USD THOUSAND) 63 TABLE 15 NEUROVASCULAR DEVICES MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026 64 TABLE 16 MEDTRONIC: FLOW DIVERTER FOR COMPLEX INTRACRANIAL ANEURYSMS 66 TABLE 17 PHENOX: ADVANCED FLOW DIVERTER WITH ENHANCED DELIVERABILITY 66 TABLE 18 STRYKER: STENT RETRIEVER THROMBECTOMY FOR ACUTE IN-STENT THROMBOSIS 66 TABLE 19 US-ADJUSTED RECIPROCAL TARIFF RATES 68 TABLE 20 NEUROVASCULAR DEVICES MARKET: LIST OF MAJOR PATENTS, 2022–2025 75 TABLE 21 TOP USE CASES AND MARKET POTENTIAL 76 TABLE 22 NEUROVASCULAR DEVICES MARKET: CASE STUDIES RELATED TO GEN AI IMPLEMENTATION 77 TABLE 23 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 77 TABLE 24 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79 TABLE 25 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79 TABLE 26 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80 TABLE 27 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81 TABLE 28 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81 TABLE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS BY DISEASE PATHOLOGY 86 TABLE 30 KEY BUYING CRITERIA FOR TOP APPLICATIONS 86 TABLE 31 ADOPTION BARRIERS & INTERNAL CHALLENGES 87 TABLE 32 NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 92 TABLE 33 NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 93 TABLE 34 NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY REGION, 2023–2030 (USD MILLION) 93 TABLE 35 EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY REGION, 2023–2030 (USD MILLION) 94 TABLE 36 EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 94 TABLE 37 EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY REGION, 2023–2030 (THOUSAND UNITS) 95 TABLE 38 BARE DETACHABLE COILS MARKET FOR CEREBRAL ANEURYSMS, BY REGION, 2023–2030 (USD MILLION) 96 TABLE 39 COATED DETACHABLE COILS MARKET FOR CEREBRAL ANEURYSMS, BY REGION, 2023–2030 (USD MILLION) 97 TABLE 40 FLOW DIVERSION DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY REGION, 2023–2030 (USD MILLION) 98 TABLE 41 INTRACRANIAL STENTS MARKET FOR CEREBRAL ANEURYSMS, BY REGION, 2023–2030 (USD MILLION) 98 TABLE 42 INTRACRANIAL STENTS MARKET FOR CEREBRAL ANEURYSMS, BY REGION, 2023–2030 (THOUSAND UNITS) 99 TABLE 43 OTHER DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY REGION, 2023–2030 (USD MILLION) 99 TABLE 44 NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY REGION, 2023–2030 (USD MILLION) 100 TABLE 45 NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE 2023–2030 (USD MILLION) 101 TABLE 46 CLOT RETRIEVER DEVICES MARKET FOR ISCHEMIC STROKES, BY REGION, 2023–2030 (USD MILLION) 101 TABLE 47 CLOT RETRIEVER DEVICES MARKET FOR ISCHEMIC STROKES, BY REGION, 2023–2030 (THOUSAND UNITS) 102 TABLE 48 SUCTION & ASPIRATION DEVICES MARKET FOR ISCHEMIC STROKES, BY REGION, 2023–2030 (USD MILLION) 103 TABLE 49 VASCULAR SNARES MARKET FOR ISCHEMIC STROKES, BY REGION, 2023–2030 (USD MILLION) 103 TABLE 50 BALLOON CATHETERS MARKET FOR ISCHEMIC STROKES, BY REGION, 2023–2030 (USD MILLION) 104 TABLE 51 OTHER DEVICES MARKET FOR ISCHEMIC STROKES, BY REGION, 2023–2030 (USD MILLION) 105 TABLE 52 NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY REGION, 2023–2030 (USD MILLION) 106 TABLE 53 NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 106 TABLE 54 CAROTID ARTERY STENTS MARKET FOR CAROTID ARTERY STENOSIS, BY REGION, 2023–2030 (USD MILLION) 107 TABLE 55 CAROTID ARTERY STENTS MARKET FOR CAROTID ARTERY STENOSIS, BY REGION, 2023–2030 (THOUSAND UNITS) 107 TABLE 56 EMBOLIC PROTECTION DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY REGION, 2023–2030 (USD MILLION) 108 TABLE 57 BALLOON CATHETERS MARKET FOR CAROTID ARTERY STENOSIS, BY REGION, 2023–2030 (USD MILLION) 109 TABLE 58 NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATION & FISTULAS, BY REGION, 2023–2030 (USD MILLION) 109 TABLE 59 NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATION & FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 110 TABLE 60 LIQUID EMBOLIC AGENTS MARKET FOR ARTERIOVENOUS MALFORMATION & FISTULAS, BY REGION, 2023–2030 (USD MILLION) 110 TABLE 61 OCCLUSION BALLOON CATHETERS MARKET FOR ARTERIOVENOUS MALFORMATION & FISTULAS, BY REGION, 2023–2030 (USD MILLION) 111 TABLE 62 MICROCATHETERS MARKET FOR ARTERIOVENOUS MALFORMATION & FISTULAS, BY REGION, 2023–2030 (USD MILLION) 111 TABLE 63 NEUROVASCULAR DEVICES MARKET FOR OTHER DISEASE PATHOLOGIES, BY REGION, 2023–2030 (USD MILLION) 112 TABLE 64 NEUROVASCULAR DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 114 TABLE 65 NEUROVASCULAR DEVICES MARKET FOR HOSPITALS AND AMBULATORY SURGICAL CENTERS, BY REGION, 2023–2030 (USD MILLION) 115 TABLE 66 NEUROVASCULAR DEVICES MARKET FOR SPECIALTY CLINICS, BY REGION, 2023–2030 (USD MILLION) 115 TABLE 67 NEUROVASCULAR DEVICES MARKET FOR RESEARCH LABORATORIES AND ACADEMIC INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 116 TABLE 68 NEUROVASCULAR DEVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 118 TABLE 69 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 70 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 121 TABLE 71 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, 2023–2030 (USD MILLION) 121 TABLE 72 NORTH AMERICA: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 122 TABLE 73 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 122 TABLE 74 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 122 TABLE 75 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 123 TABLE 76 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 123 TABLE 77 US: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 124 TABLE 78 US: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, 2023–2030 (USD MILLION) 124 TABLE 79 US: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 125 TABLE 80 US: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 125 TABLE 81 US: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 125 TABLE 82 US: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 126 TABLE 83 US: NEUROVASCULAR DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 126 TABLE 84 CANADA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 127 TABLE 85 CANADA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 127 TABLE 86 CANADA: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 128 TABLE 87 CANADA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 128 TABLE 88 CANADA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 128 TABLE 89 CANADA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 129 TABLE 90 CANADA: NEUROVASCULAR DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 129 TABLE 91 EUROPE: NEUROVASCULAR DEVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 92 EUROPE: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 131 TABLE 93 EUROPE: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 131 TABLE 94 EUROPE: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 131 TABLE 95 EUROPE: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 132 TABLE 96 EUROPE: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 132 TABLE 97 EUROPE: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 132 TABLE 98 EUROPE: NEUROVASCULAR DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 133 TABLE 99 GERMANY: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 134 TABLE 100 GERMANY: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 134 TABLE 101 GERMANY: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 134 TABLE 102 GERMANY: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 135 TABLE 103 GERMANY: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 135 TABLE 104 GERMANY: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 135 TABLE 105 GERMANY: NEUROVASCULAR DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 136 TABLE 106 FRANCE: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 137 TABLE 107 FRANCE: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 137 TABLE 108 FRANCE: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 138 TABLE 109 FRANCE: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 138 TABLE 110 FRANCE: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 138 TABLE 111 FRANCE: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 139 TABLE 112 FRANCE: NEUROVASCULAR DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 139 TABLE 113 UK: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 140 TABLE 114 UK: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 140 TABLE 115 UK: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 141 TABLE 116 UK: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 141 TABLE 117 UK: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 141 TABLE 118 UK: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 142 TABLE 119 UK: NEUROVASCULAR DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 142 TABLE 120 ITALY: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 143 TABLE 121 ITALY: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 143 TABLE 122 ITALY: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 143 TABLE 123 ITALY: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 144 TABLE 124 ITALY: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 144 TABLE 125 ITALY: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 144 TABLE 126 ITALY: NEUROVASCULAR DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 145 TABLE 127 SPAIN: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 146 TABLE 128 SPAIN: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 146 TABLE 129 SPAIN: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 146 TABLE 130 SPAIN: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 147 TABLE 131 SPAIN: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 147 TABLE 132 SPAIN: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 147 TABLE 133 SPAIN: NEUROVASCULAR DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 148 TABLE 134 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 149 TABLE 135 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 149 TABLE 136 REST OF EUROPE: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 149 TABLE 137 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 150 TABLE 138 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 150 TABLE 139 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 150 TABLE 140 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 151 TABLE 141 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 142 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 153 TABLE 143 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 154 TABLE 144 ASIA PACIFIC: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 154 TABLE 145 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 154 TABLE 146 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 155 TABLE 147 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 155 TABLE 148 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 155 TABLE 149 JAPAN: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 156 TABLE 150 JAPAN: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 157 TABLE 151 JAPAN: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 157 TABLE 152 JAPAN: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 157 TABLE 153 JAPAN: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 158 TABLE 154 JAPAN: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 158 TABLE 155 JAPAN: NEUROVASCULAR DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 158 TABLE 156 CHINA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 159 TABLE 157 CHINA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 160 TABLE 158 CHINA: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 160 TABLE 159 CHINA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 160 TABLE 160 CHINA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 161 TABLE 161 CHINA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 161 TABLE 162 CHINA: NEUROVASCULAR DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 161 TABLE 163 INDIA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 162 TABLE 164 INDIA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 163 TABLE 165 INDIA: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 163 TABLE 166 INDIA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 163 TABLE 167 INDIA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 164 TABLE 168 INDIA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 164 TABLE 169 INDIA: NEUROVASCULAR DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 164 TABLE 170 AUSTRALIA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 165 TABLE 171 AUSTRALIA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 166 TABLE 172 AUSTRALIA: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 166 TABLE 173 AUSTRALIA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 166 TABLE 174 AUSTRALIA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 167 TABLE 175 AUSTRALIA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 167 TABLE 176 AUSTRALIA: NEUROVASCULAR DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 167 TABLE 177 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 168 TABLE 178 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 168 TABLE 179 SOUTH KOREA: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 169 TABLE 180 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 169 TABLE 181 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 169 TABLE 182 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 170 TABLE 183 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 170 TABLE 184 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 171 TABLE 185 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 171 TABLE 186 REST OF ASIA PACIFIC: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 171 TABLE 187 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 172 TABLE 188 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 172 TABLE 189 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 172 TABLE 190 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 173 TABLE 191 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 192 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 174 TABLE 193 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 174 TABLE 194 LATIN AMERICA: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 175 TABLE 195 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 175 TABLE 196 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 175 TABLE 197 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 176 TABLE 198 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 176 TABLE 199 BRAZIL: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 177 TABLE 200 BRAZIL: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 177 TABLE 201 BRAZIL: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 178 TABLE 202 BRAZIL: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 178 TABLE 203 BRAZIL: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 178 TABLE 204 BRAZIL: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 179 TABLE 205 BRAZIL: NEUROVASCULAR DEVICES MARKET, BY END USER 2023–2030 (USD MILLION) 179 TABLE 206 MEXICO: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 180 TABLE 207 MEXICO: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 180 TABLE 208 MEXICO: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 180 TABLE 209 MEXICO: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 181 TABLE 210 MEXICO: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 181 TABLE 211 MEXICO: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 181 TABLE 212 MEXICO: NEUROVASCULAR DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 182 TABLE 213 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 182 TABLE 214 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 183 TABLE 215 REST OF LATIN AMERICA: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 183 TABLE 216 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 183 TABLE 217 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 184 TABLE 218 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 184 TABLE 219 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 184 TABLE 220 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET, BY SUBREGION, 2023–2030 (USD MILLION) 186 TABLE 221 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 186 TABLE 222 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 187 TABLE 223 MIDDLE EAST & AFRICA: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 187 TABLE 224 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 187 TABLE 225 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 188 TABLE 226 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 188 TABLE 227 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 188 TABLE 228 GCC COUNTRIES: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 190 TABLE 229 GCC COUNTRIES: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 190 TABLE 230 GCC COUNTRIES: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 190 TABLE 231 GCC COUNTRIES: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 191 TABLE 232 GCC COUNTRIES: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 191 TABLE 233 GCC COUNTRIES: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 191 TABLE 234 GCC COUNTRIES: NEUROVASCULAR DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 192 TABLE 235 REST OF MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 193 TABLE 236 REST OF MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 193 TABLE 237 REST OF MIDDLE EAST & AFRICA: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 193 TABLE 238 REST OF MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 194 TABLE 239 REST OF MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 194 TABLE 240 REST OF MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 194 TABLE 241 REST OF MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 195 TABLE 242 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN NEUROVASCULAR DEVICES MARKET, JANUARY 2022–JUNE 2025 197 TABLE 243 NEUROVASCULAR DEVICE MARKET: DEGREE OF COMPETITION 200 TABLE 244 NEUROVASCULAR DEVICES MARKET: REGIONAL FOOTPRINT, 2024 205 TABLE 245 NEUROVASCULAR DEVICES MARKET: DISEASE PATHOLOGY FOOTPRINT, 2024 206 TABLE 246 NEUROVASCULAR DEVICES MARKET: BY END USER FOOTPRINT 207 TABLE 247 NEUROVASCULAR DEVICES MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS, 2024 210 TABLE 248 NEUROVASCULAR DEVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY PRODUCT TYPE AND REGION, 2024 211 TABLE 249 NEUROVASCULAR DEVICES MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–NOVEMBER 2025 214 TABLE 250 NEUROVASCULAR DEVICES MARKET: DEALS, JANUARY 2022–NOVEMBER 2025 216 TABLE 251 NEUROVASCULAR DEVICES MARKET: EXPANSIONS, JANUARY 2022–NOVEMBER 2025 217 TABLE 252 NEUROVASCULAR DEVICES MARKET: OTHER DEVELOPMENTS, JANUARY 2022–NOVEMBER 2025 217 TABLE 253 STRYKER: COMPANY OVERVIEW 218 TABLE 254 STRYKER: PRODUCTS OFFERED 219 TABLE 255 STRYKER: PRODUCT LAUNCHES & APPROVALS 224 TABLE 256 STRYKER: DEALS 225 TABLE 257 STRYKER: EXPANSIONS 226 TABLE 258 MEDTRONIC: COMPANY OVERVIEW 228 TABLE 259 MEDTRONIC: PRODUCTS OFFERED 229 TABLE 260 MEDTRONIC: PRODUCT LAUNCHES & APPROVALS 231 TABLE 261 MEDTRONIC: EXPANSIONS 232 TABLE 262 JOHNSON & JOHNSON: BUSINESS OVERVIEW 233 TABLE 263 JOHNSON & JOHNSON: PRODUCTS OFFERED 234 TABLE 264 JOHNSON & JOHNSON: PRODUCT LAUNCHES & APPROVALS 235 TABLE 265 JOHNSON & JOHNSON SERVICES, INC.: OTHER DEVELOPMENTS 236 TABLE 266 TERUMO CORPORATION: COMPANY OVERVIEW 238 TABLE 267 TERUMO CORPORATION: PRODUCTS OFFERED 239 TABLE 268 TERUMO CORPORATION: PRODUCT LAUNCHES & APPROVALS 240 TABLE 269 TERUMO CORPORATION: DEALS 242 TABLE 270 TERUMO CORPORATION: EXPANSIONS 242 TABLE 271 TERUMO CORPORATION: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 243 TABLE 272 PENUMBRA, INC.: COMPANY OVERVIEW 244 TABLE 273 PENUMBRA, INC.: PRODUCTS OFFERED 245 TABLE 274 PENUMBRA, INC.: PRODUCT LAUNCHES & APPROVALS 246 TABLE 275 MICROPORT SCIENTIFIC CORPORATION: COMPANY OVERVIEW 248 TABLE 276 MICROPORT SCIENTIFIC CORPORATION: PRODUCTS OFFERED 249 TABLE 277 MICROPORT SCIENTIFIC CORPORATION: PRODUCT LAUNCHES & APPROVALS 250 TABLE 278 BALT GROUP: COMPANY OVERVIEW 252 TABLE 279 BALT GROUP: PRODUCTS OFFERED 252 TABLE 280 BALT GROUP: DEALS 253 TABLE 281 BALT GROUP: EXPANSIONS 253 TABLE 282 KANEKA CORPORATION: COMPANY OVERVIEW 255 TABLE 283 KANEKA CORPORATION: PRODUCTS OFFERED 256 TABLE 284 KANEKA CORPORATION: PRODUCT LAUNCHES & APPROVALS 257 TABLE 285 KANEKA CORPORATION: DEALS 257 TABLE 286 PHENOX GMBH (WALLABY MEDICAL): COMPANY OVERVIEW 259 TABLE 287 PHENOX GMBH (WALLABY MEDICAL): PRODUCTS OFFERED 259 TABLE 288 PHENOX GMBH (WALLABY MEDICAL): PRODUCT LAUNCHES & APPROVALS 260 TABLE 289 ASAHI INTECC CO., LTD.: COMPANY OVERVIEW 262 TABLE 290 ASAHI INTECC CO., LTD.: PRODUCTS OFFERED 263 TABLE 291 ASAHI INTECC CO., LTD: DEALS 264 TABLE 292 ASAHI INTECC CO., LTD: EXPANSIONS 264 TABLE 293 ACHIEVA MEDICAL (PEIJIA MEDICAL): COMPANY OVERVIEW 266 TABLE 294 ACHIEVA MEDICAL (PEIJIA MEDICAL): PRODUCTS OFFERED 266 TABLE 295 ACHIEVA MEDICAL (PEIJIA MEDICAL): DEALS 267 TABLE 296 RAPID MEDICAL: COMPANY OVERVIEW 268 TABLE 297 RAPID MEDICAL: PRODUCTS OFFERED 268 TABLE 298 RAPID MEDICAL: PRODUCT LAUNCHES & APPROVALS 269 TABLE 299 RAPID MEDICAL: DEALS 269 TABLE 300 JAPAN LIFELINE CO., LTD: COMPANY OVERVIEW 270 TABLE 301 JAPAN LIFELINE CO., LTD: PRODUCTS OFFERED 271 TABLE 302 ACANDIS GMBH: COMPANY OVERVIEW 272 TABLE 303 ACANDIS GMBH: PRODUCTS OFFERED 272 TABLE 304 ACANDIS GMBH: EXPANSIONS 273 TABLE 305 EVASC MEDICAL SYSTEM CORP: COMPANY OVERVIEW 274 TABLE 306 EVASC MEDICAL SYSTEM CORP: PRODUCTS OFFERED 274 TABLE 307 EVASC MEDICAL SYSTEM CORP: PRODUCT LAUNCHES & APPROVALS 274 TABLE 308 EVASC MEDICAL SYSTEM CORP: EXPANSIONS 275 TABLE 309 RESEARCH ASSUMPTIONS 298 TABLE 310 RISK ASSESSMENT 299 FIGURE 1 MARKETS COVERED & REGIONAL SCOPE 32 FIGURE 2 YEARS CONSIDERED 33 FIGURE 3 MARKET SCENARIO 35 FIGURE 4 NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2025 VS. 2030 (USD MILLION) 36 FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN NEUROVASCULAR DEVICES MARKET 36 FIGURE 6 DISRUPTIVE TRENDS IMPACTING GROWTH OF NEUROVASCULAR DEVICES MARKET 37 FIGURE 7 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN NEUROVASCULAR DEVICES MARKET, 2024 38 FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 39 FIGURE 9 INCREASE IN NUMBER OF DISEASES RELATED TO NEUROLOGICAL DISORDERS SUCH AS CEREBRAL ANEURYSMS AND STROKES TO DRIVE MARKET GROWTH 40 FIGURE 10 CEREBRAL ANEURYSMS SEGMENT ACCOUNTED FOR HIGHEST MARKET SHARE IN ASIA PACIFIC 41 FIGURE 11 CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 42 FIGURE 12 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD, 2025–2030 42 FIGURE 13 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 43 FIGURE 14 DIABETES CARE DEVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 44 FIGURE 15 NEUROVASCULAR DEVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 51 FIGURE 16 NEUROVASCULAR DEVICES MARKET: SUPPLY CHAIN ANALYSIS 56 FIGURE 17 NEUROVASCULAR DEVICES MARKET: VALUE CHAIN ANALYSIS 57 FIGURE 18 NEUROVASCULAR DEVICES MARKET: ROLE IN ECOSYSTEM 59 FIGURE 19 NEUROVASCULAR DEVICES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 65 FIGURE 20 NEUROVASCULAR DEVICES MARKET: FUNDING (USD MILLION) AND NUMBER OF DEALS, 2019–2023 65 FIGURE 21 TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR NEUROVASCULAR DEVICES MARKET, JANUARY 2014–DECEMBER 2024 74 FIGURE 22 TOP PATENT APPLICANT COUNTRIES FOR NEUROVASCULAR DEVICES MARKET, JANUARY 2014–DECEMBER 2024 75 FIGURE 23 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS BY DISEASE PATHOLOGY 85 FIGURE 24 KEY BUYING CRITERIA, BY DISEASE PATHOLOGY 86 FIGURE 25 NEUROVASCULAR DEVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 119 FIGURE 26 NEUROVASCULAR DEVICES MARKET: NORTH AMERICA SNAPSHOT 120 FIGURE 27 NEUROVASCULAR DEVICES MARKET: ASIA PACIFIC SNAPSHOT 152 FIGURE 28 REVENUE SHARE ANALYSIS OF KEY PLAYERS IN NEUROVASCULAR DEVICES MARKET, 2022–2024 (USD MILLION) 199 FIGURE 29 MARKET SHARE ANALYSIS OF KEY PLAYERS IN NEUROVASCULAR DEVICES MARKET, 2024 199 FIGURE 30 NEUROVASCULAR DEVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 203 FIGURE 31 NEUROVASCULAR DEVICES MARKET: COMPANY FOOTPRINT, 2024 204 FIGURE 32 NEUROVASCULAR DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 209 FIGURE 33 EV/EBITDA OF KEY VENDORS, 2024 211 FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024 212 FIGURE 35 NEUROVASCULAR DEVICES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 213 FIGURE 36 NEUROVASCULAR DEVICES MARKET: R&D EXPENDITURE OF KEY PLAYERS, 2022–2024 214 FIGURE 37 STRYKER: COMPANY SNAPSHOT, 2024 219 FIGURE 38 MEDTRONIC: COMPANY SNAPSHOT, 2024 229 FIGURE 39 JOHNSON & JOHNSON: COMPANY SNAPSHOT, 2024 234 FIGURE 40 TERUMO CORPORATION: COMPANY SNAPSHOT, 2024 239 FIGURE 41 PENUMBRA, INC.: COMPANY SNAPSHOT, 2024 245 FIGURE 42 MICROPORT SCIENTIFIC CORPORATION: COMPANY SNAPSHOT, 2024 249 FIGURE 43 KANEKA CORPORATION: COMPANY SNAPSHOT, 2024 256 FIGURE 44 ASAHI INTECC CO., LTD: COMPANY SNAPSHOT, 2024 263 FIGURE 45 JAPAN LIFELINE CO., LTD: COMPANY SNAPSHOT, 2024 270 FIGURE 46 RESEARCH DESIGN 286 FIGURE 47 NEUROVASCULAR DEVICES MARKET: KEY DATA FROM SECONDARY SOURCES 288 FIGURE 48 NEUROVASCULAR DEVICES MARKET: KEY PRIMARY SOURCES (DEMAND AND SUPPLY SIDE) 288 FIGURE 49 KEY DATA FROM PRIMARY SOURCES 289 FIGURE 50 KEY INSIGHTS FROM INDUSTRY EXPERTS 290 FIGURE 51 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 290 FIGURE 52 BREAKDOWN OF PRIMARY INTERVIEWS, BY END USER, DESIGNATION, AND REGION 291 FIGURE 53 MARKET SIZE ESTIMATION PROCESS THROUGH REVENUE DATA 292 FIGURE 54 US: REVENUE SHARE ANALYSIS FOR STRYKER, 2024 292 FIGURE 55 SUPPLY SIDE ANALYSIS, 2024 293 FIGURE 56 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 293 FIGURE 57 BOTTOM-UP APPROACH 294 FIGURE 58 CAGR PROJECTIONS FROM DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES ANALYSIS, 2025–2030 295 FIGURE 59 TOP-DOWN APPROACH 296 FIGURE 60 DATA TRIANGULATION METHODOLOGY 297 FIGURE 61 FACTOR ANALYSIS 298

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們